|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Patients
Our progress, goals and achievements are underscored by a deep
commitment to creating, sustaining and growing the unique
patient relevance of our therapies, science and relationships.
In addition to the advancement of our products and clinical
studies, this fundamental focus on patients is also evidenced by
our collaborative research ventures, our patient assistance
programmes, our intellectual property estate enabling the
advancement of innovation, and the widespread, patient-facing
outreach of our employees in the communities in which we work
and live.
Alzheimer’s
Drug Discovery Foundation (ADDF)
ADDF, a biomedical venture philanthropy, is the only public
charity solely dedicated to rapidly accelerating the discovery
and development of drugs to prevent, treat and cure
Alzheimer’s disease and cognitive aging. On 16 April
2008, ADDF and Elan announced the winners of their third annual
research award programme, Novel Approaches to Drug Discovery for
Alzheimer’s Disease. Four international scientists received
a total of $530,000 in grant funding.
The
Parkinson’s Institute and Clinical Center
In addition to our internal programmes for Parkinson’s
disease, we collaborate with world-class experts to expand the
body of scientific knowledge around this disease. Our
researchers have worked with scientists from the
Parkinson’s Institute and Clinical Center and have made
significant progress in developing a new animal model, which
could enable us to evaluate new treatment approaches.
The
Michael J. Fox Foundation for Parkinson’s
Research
Since 2007, our efforts with the Michael J. Fox Foundation for
Parkinson’s Research have included a grant programme, Novel
Approaches to Drug Discovery, designed to identify and fund
promising projects, to help them advance more quickly from the
lab to the clinic.
With a strong focus on the development of disease-modifying
therapies for Parkinson’s disease, Novel Approaches to Drug
Discovery provides funding for projects of up to one year’s
duration. Ideal proposals focus on efforts to develop promising
biological targets into novel disease-modifying therapeutic
strategies. Novel Approaches to Drug Discovery holds unique
potential to provide awardees from both academic and biotech
institutions with a clear opportunity for follow-on funding and
collaboration for further development. We have an option for a
right of first negotiation for any promising approaches or
materials that arise out of this programme.
The
Alzheimer’s Association
The Alzheimer’s Association is the leading voluntary
U.S. health organisation in Alzheimer’s care, support
and research, with a mission “to eliminate Alzheimer’s
disease through the advancement of research; to provide and
enhance care and support for all affected; and to reduce the
risk of dementia through the promotion of brain health”.
Our multi-faceted relationship with the Alzheimer’s
Association includes participating in the Alzheimer’s
Association Research Roundtable, a consortium of scientific
thought-leaders working to facilitate the development and
implementation of new treatments for Alzheimer’s disease.
Table of Contents
Corporate Social
Responsibility: Our Commitments and Goals
National
Pain Foundation
The American Pain Society
Severe chronic pain is a condition that requires a community of
support and education. We have ongoing patient education
initiatives with the National Pain Foundation and the American
Pain Society, and we are proud to support their efforts to
provide reliable information and services to patients and
healthcare providers.
The
Alzheimer’s Society of Ireland
The Alzheimer’s Society of Ireland (ASI) provides care and
support for those suffering from dementia and to their families
and caregivers. Our support of ASI has encompassed a number of
important fund-raising events, including the annual Tea Day
national fundraising initiative, which we have supported at both
a corporate and a hands-on level.
The
Multiple Sclerosis Society
Multiple Sclerosis Ireland The Crohn’s and Colitis Foundation of America
Elan and our employees participated in and offered significant
fund-raising support to the Multiple Sclerosis Society, Multiple
Sclerosis Ireland and the Crohn’s and Colitis Foundation of
America. Last year, dozens of employees participated in
awareness-raising and fund-raising events sponsored by these
associations, collectively raising more than $30,000 in support
of key programmes and initiatives.
Tysabri
Financial Assistance Programme
We, along with our collaborator on Tysabri, Biogen Idec,
provide Tysabri patients a wide range of support services
and programmes to optimise access to Tysabri in the
United States. We partner patients with a Financial Assistance
Counselor to develop the best financial solution for accessing
Tysabri therapy, helping to ensure that no patient is
denied treatment based solely on financial reasons. Financial
assistance programmes encompass a number of options; are
tailored to address the various needs of patients, including
those uninsured, privately insured, or insured through Medicare;
and include a co-pay assistance programme with a low monthly
cap, subject to annual enrollment and income limit
qualifications.
|
| |||||||
